Reach Us +44-1647-403003
Effects Of Palladium-based Compounds On Human Neuroblastoma Cell Lines With Acquired Resistance To Platinum Drugs | 60880
ISSN: 2471-8556

Oncology & Cancer Case Reports
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Effects of Palladium-based Compounds on human neuroblastoma cell lines with acquired resistance to platinum drugs


Adewale Victor Aderemi

Osun State University, Nigeria

Posters & Accepted Abstracts: Oncol Cancer Case Rep

DOI: 10.4172/2471-8556.C1.003

Despite significant advances, neuroblastoma remains one of the most difficult childhood cancers to cure, with less than 40% of patients with high-risk disease being long-term survivors. Resistance acquisition to chemotherapy is a major cause of treatment failure in high-risk cases. Here, we tested the effects of novel palladium-based (SW005c, SW009b, SW012a, SW017a and SW018a) compounds on the viability of the human neuroblastoma cell line UKF-NB-3 and its sub-lines adapted to the clinically approved platinum drugs cisplatin (UKF-NB-3rCDDP1000), carboplatin (UKF-NB-3rCARBO2000), and oxaliplatin (UKF-NB-3rOXALI2000) by MTT assay. The palladium compounds SW005c, SW009b, SW012a, SW017a, and SW018a interfered with the viability of the cells in low micromolar concentrations (1.4μM – 4μM). Although some degree of heterogeneity in the response of the cell lines to the palladium compounds was observed, in particular with regard to SW017a and SW018a, there was no pattern indicating that acquired platinum drug-resistance would be associated with decreased sensitivity to the investigated palladium compounds. This suggests that the anti-cancer mechanism of action of the palladium compounds differs from that of the approved platinum drugs. In conclusion, the newly synthesised palladium-based compounds should be further studied in additional cell line models and animal experiments.

Adewale holds an MBBS degree from University of Ilorin, Nigeria, and MSc in Biochemistry from the University of Kent, UK. While waiting to start his PhD later in the year at the University of Manchester, UK, he currently lectures in the Department of Biochemistry, Osun State University, Osogbo, Nigeria. He has 4 publications in reputable journals.

Email: [email protected] [email protected]

Relevant Topics